U.S. Medical Centers Need a New Model for Drug Discovery and Development – Harvard Business Review

by Anaeze C. Offodile II, Kushal T. Kadakia, Yashodhara Dash, Whitney Snider, Joseph C. Wu and Selwyn M. Vickers
For more than 50 years, U.S. academic medical centers (AMCs) have been the global engine for pharmaceutical innovation. These university-affiliated hospitals are dedicated to fulfilling the mission areas of medical education, scientific research, and patient care. They have developed a distinctive innovation model in which patient care inspires research questions, public investment supports discovery, and public-private partnerships enable the translation of these breakthroughs into clinical practice. But U.S. AMCs are now facing a major challenge from China, which has emerged as a major rival in the last decade. Its pharmaceuticals R&D sector is on track to become the global industry leader, displacing its U.S. counterpart.
Harvard Business Publishing:
Copyright ©2026 Harvard Business School Publishing. All rights reserved. Harvard Business Publishing is an affiliate of Harvard Business School.

source